- |||||||||| Medication-Induced QTc Prolongation in Parkinson’s Disease-Related Psychosis: A Literature Review (Biscayne Ballroom) - Feb 14, 2020 - Abstract #MDSPAS2020MDS_PAS_77;
While PD patients exhibiting psychotic symptoms are treated with medications targeting multiple neurotransmitters, it is possible that PD patients exhibit different QTc prolongation profiles following antipsychotic use as compared to other patient populations. Neuroimaging evidence from a 1997 paper demonstrated cardiac sympathetic denervation in PD, which has been confirmed by many studies since, (23) and additional studies are needed to determine whether these changes could affect QTc intervals in PD patients treated with antipsychotics.
- |||||||||| rivastigmine / Generic mfg.
[VIRTUAL] AN OBJECT PATTERN SEPARATION TASK IDENTIFIES EVIDENCE OF ENHANCED HIPPOCAMPAL NEUROGENESIS IN DEMENTIA WITH LEWY BODIES: PREVIOUSLY UNANALYSED DATA FROM A PUBLISHED STUDY (Hall M) - Jan 6, 2020 - Abstract #AATADPD2020AAT_ADPD_288;
The data from the task were analysed using MMRM. Results The findings showed a highly significant interaction term indicating that the two types of stimuli were differentially affected by placebo and rivastigmine over the 23-week study period Conclusions This is to our knowledge the first study to identify that object pattern separation can be therapeutically improved in DLB patients DLB Patients on placebo significantly declined on the Pattern Separation measure over 23 weeks, while those treated with Rivastigmine showed a significant improvement over this period The difference between placebo and Rivastigmine on the Pattern Separation measure had a clinically relevant effect size (d=0.51) The data are entirely consistent with pre-clinical and post-mortem data showing that neurogenesis is compromised in DLB, and also with pre-clinical data that rivastigmine can improve neurogenesis
- |||||||||| donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
[VIRTUAL] USING CHOLINESTERASE INHIBITORS TO TREAT ALZHEIMER PATIENTS AT DIFFERENT STAGES OF THE DISEASE. WHAT WE HAVE LEARNED IN 25Y EXPERIENCE! (Hall E) - Jan 6, 2020 - Abstract #AATADPD2020AAT_ADPD_153;
ChEI are clinically efficacious at mild to moderate , as well as at severe stages of AD.2 Female MCI with APOE4 + respond better than male MCI.3 generally, higher doses are more effective in severe cases.4 there are positive clinical therapeutic dose-response effects at any stage of the disease.5 rapidly progressing patients in moderate stages are more likely to respond .6 the three most used ChEI (donepezil, rivastigmine, galantamine) do not show clinically significant differences .7 beneficial, symptomatic effects may persist over 1-2 years and their administration should be continued as long as the patients are benefiting.8 valuable indications for ChEI therapy are : Lewy body dementia ; Parkinson dementia, Mixed AD and Vascular Dementia.9 female and male AD patients show differences in disease progression and do not respond similarly to CEIhhhEI. Conclusions a remarkable progress in our knowledge has been obtained regarding the use of ChEI in AD ,allowing for a more personalized treatment.
- |||||||||| Journal: Lewy body dementia: therapeutic propositions according to evidence based medicine and practice. (Pubmed Central) - Dec 25, 2019
Acetylcholinesterase inhibitors (donepezil or rivastigmine) were studied in several double-blind placebo-controlled studies...Hallucinations may require antipsychotic treatment and the best documented drug is clozapine...Some therapeutic trials with modafinil were proposed to improve diurnal hypersomnia...This strategy underlines the importance to improve cholinergic deficit and sleep disturbances. It also stresses the importance of a careful revision of all drugs administered to the patients with a peculiar attention to the anticholinergic treatment.
- |||||||||| aspirin / Generic mfg., rivastigmine / Generic mfg.
Preclinical, Journal: Characterization of aspirin esterase activity in health and disease: in vitro and ex vivo studies. (Pubmed Central) - Dec 23, 2019
This result suggests the absence of any influence of disease state, drug treatments, and comorbidities on plasma esterase and the inability of ASA intake to induce esterase function. In conclusion, the method here developed allows a better characterisation of ASA esterase activity and could be helpful to define the PK-related determinants of ASA responsiveness in order to personalise regimen in specific pathological conditions.
- |||||||||| Comtan (entacapone) / Novartis, Orion, rivastigmine / Generic mfg.
Clinical, Journal: Parkinson's syndromes in geriatric patients : Epidemiological, clinical and therapeutic characteristics (Pubmed Central) - Dec 19, 2019
Rivastigmine is indicated in mild to moderate Parkinson's dementia and furthermore can possibly improve gait stability. Speech therapy, as well as physical and occupational therapy, including the Parkinson's disease-specific Lee Silverman voice treatment are indispensable components of the multiprofessional treatment concept.
- |||||||||| rivastigmine / generics
Journal: Electrochemical MIP Sensor for Butyrylcholinesterase. (Pubmed Central) - Dec 8, 2019
The response was linear between 50 pM and 2 nM concentrations of BuChE with a detection limit of 14.7 pM. In addition to the high sensitivity for BuChE, the sensor responded towards pseudo-irreversible inhibitors in the lower mM range.
- |||||||||| donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., memantine / Generic mfg.
Journal: Cholinesterase as a Target for Drug Development in Alzheimer's Disease. (Pubmed Central) - Nov 28, 2019
Herein, we describe the role of acetylcholine sterase (AChE) and related hypothesis in AD along with the pharmacological and chemical aspects of the available cholinesterase inhibitors. This chapter discusses the development of several congeners and hybrids of available cholinesterase inhibitors along with their binding patterns in enzyme active sites.
- |||||||||| donepezil / generics, memantine / generics, rivastigmine / generics
Clinical, Journal: Patterns of Dementia Treatment and Frank Prescribing Errors in Older Adults With Parkinson Disease. (Pubmed Central) - Nov 28, 2019
Dementia medication use by persons with Parkinson disease varies by race/ethnicity and sex; potentially inappropriate prescribing is common among those being treated for cognitive impairment and varies by race/ethnicity, sex, and geography. These findings may serve as national and local targets for improving care quality and outcomes for persons with Parkinson disease.
- |||||||||| Duragesic (fentanyl) / J&J
Journal: Sex-by-formulation interaction in bioequivalence trials with transdermal patches. (Pubmed Central) - Nov 27, 2019
The sex-by-formulation interaction detected in some pharmacokinetic parameters of some studies is excluded when the study is repeated, which shows that these results are not reproducible. There is no evidence to require bioequivalence demonstration for transdermal patches in males and females separately.
- |||||||||| rivastigmine / generics
Review, Journal: Use of Cholinesterase Inhibitors in Non-Alzheimer's Dementias. (Pubmed Central) - Nov 27, 2019
In FTD patients, cholinesterase inhibitors were mostly associated with worsening of cognitive and behavioral symptoms. In non-AD dementias, cholinesterase inhibitors were well tolerated, with increased reports of mild to moderate cholinergic side effects and a non-significant trend for increased cardio and cerebrovascular events with rivastigmine in VaD, justifying their cautious use on a case-by-case basis, especially when there is evidence for cholinergic deficit.
- |||||||||| rivastigmine / generics
Journal: Synthesis and Biological Evaluation of Genistein-O-alkylamine Derivatives as Potential Multifunctional Anti-Alzheimer Agents. (Pubmed Central) - Nov 19, 2019
The results showed that these derivatives had significant acetylcholinesterase (AChE) inhibitory activity; compound 5a exhibited the strongest inhibition to AChE with an IC value (0.034 μM) much lower than that of rivastigmine (6.53 μM)...The compounds did not show obvious effect on HepG2 and PC12 cell viability at the concentration of 100 μM. Therefore, these genistein derivatives can be utilized as multifunctional agents for the treatment of AD.
- |||||||||| donepezil / generics, galantamine hydrobromide / generics, rivastigmine / generics
Journal: Cognitive improvement of acetylcholinesterase inhibitors in schizophrenia. (Pubmed Central) - Nov 2, 2019
The current evidence is too weak to base recommendations on the use of acetylcholinesterase inhibitors as adjunctive treatments to antipsychotics to improve basic cognitive functions. We have limited confidence in the effect estimates.
- |||||||||| donepezil / generics, memantine / generics, rivastigmine / generics
Journal: Diagnosis and Management of Dementia: Review. (Pubmed Central) - Oct 31, 2019
Rivastigmine can be used to treat symptomatic Parkinson disease dementia...Causes of dementia can be diagnosed by medical history, cognitive and physical examination, laboratory testing, and brain imaging. Management should include both nonpharmacologic and pharmacologic approaches, although efficacy of available treatments remains limited.
- |||||||||| idalopirdine (Lu AE58054) / Lundbeck, Otsuka, Eli Lilly
Preclinical, Journal: Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson's disease. (Pubmed Central) - Oct 29, 2019
These results extend the prediction that the combined treatment with idalopirdine and an AChEI improves complex movement control and reduces the propensity for falls in patients with movement disorders. Because of the importance of finding better treatments for gait and balance deficits in PD, the present results may further motivate a clinical exploration of the usefulness of this combination treatment.
- |||||||||| ondansetron / generics, rivastigmine / generics
Clinical, Review, Journal: Pharmacological interventions for the treatment of delirium in critically ill adults. (Pubmed Central) - Oct 18, 2019
No studies reported delirium relapse, resolution of symptoms, or quality of life. The ten ongoing studies and the six studies awaiting classification that we identified, once published and assessed, may alter the conclusions of the review.
- |||||||||| olanzapine / Generic Mfg.
The D1 Positive Allosteric Modulator, DETQ, Improves Cognition and Negative Symptoms in Subchronic Phencyclidine (PCP)-Treated and Aged Mice (Bonnet Creek IX) - Oct 17, 2019 - Abstract #ACNP2019ACNP_884;
A subeffective dose (SED) of DETQ, 3mg/kg + SED olanzapine, 0.3 mg/kg, or SED rivastigmine, a cholinesterase inhibitor, also rescued NOR in sc-PCP mice, while the D2R antagonist, haloperidol.,0.3 mg/kg, and the GABAAR antagonist, gabazine, prevented rescue by DETQ...Unique Data The behavioral data in young and old mice are unique and are relevant to clinical use of DETQ for schizophrenia and aging. Ongoing behavioral and dialysis in studies in sc-PCP and aged mice treated with acute and sc-DETQ will further delineate the mechanisms by which DETQ improves memory and SI.
- |||||||||| rivastigmine / generics
Dopamine D1 Family Receptor Mechanisms in Psychiatric and Neurodegenerative Diseases (Bonnet Creek IX) - Oct 17, 2019 - Abstract #ACNP2019ACNP_882;
DETQ and LY3154207, using relevant mouse models...Meltzer will present new data on the efficacy of acute and chronic treatment with DETQ as mono and adjunctive therapy with atypical APD, and interactions with D2R antagonists, and rivastigmine, in models of SCHZ, MDD, and aging...Evidence will be presented providing a mechanistic clue to PD pathophysiology. The symposium will highlight the therapeutic potential of targeting D1R in a diverse set of diseases.
- |||||||||| Journal: France Will No More Reimburse Available Symptomatic Drugs Against Alzheimer's Disease. (Pubmed Central) - Oct 10, 2019
The evidence-based medicine related to these drugs reaches a high level in literature, whereas the clinical relevance of these treatments must be considered with co-prescription of psychosocial interventions and related approaches. As no serious pharmacovigilance signal has been provided by health authorities, the ratio of benefits/risks favors these drugs.
- |||||||||| quetiapine / Generic Mfg.
QUETIAPINE- AND RIVASTIGMINE-INDUCED NEUROLEPTIC MALIGNANT SYNDROME IN LEWY BODY DEMENTIA (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 5) - Sep 25, 2019 - Abstract #CHEST2019CHEST_3390;
NMS diagnosis requires a high index of suspicion and early identification improves outcomes. Rivastigmine use should raise suspicion of NMS with autonomic dysfunction, bland infectious work up, and concomitant neuroleptic use.
- |||||||||| risperidone / Generic Mfg., Egis, olanzapine / Generic Mfg., quetiapine / Generic Mfg.
Patterns of Lewy body dementia diagnosis and treatment in Florida (Les Muses, Level 3) - Sep 24, 2019 - Abstract #MDSCongress2019MDS_1678;
African-Americans account for a lower percent of LBD cases than the proportion of African-Americans (17%) in Florida suggesting LBD may be underdiagnosed in this population [1]. Opportunities to improve care include diagnosis amongst racial/ethnic minorities and decreased use of inappropriate antipsychotics.
- |||||||||| rivastigmine / generics
The association between frailty and Parkinson’s in the ReSPOnD trial (Agora 3 West, Level 3) - Sep 24, 2019 - Abstract #MDSCongress2019MDS_945;
Data were collected as part of the double-blind randomised controlled rivastigmine to stabilise gait in Parkinson’s (ReSPonD) trial in 130 people with Hohn and Yahr 2-3, idiopathic PD who had fallen in the year prior to enrolment...There was a high prevalence (84%) of pre-frail and frail individuals in this cohort of patients with Hoehn and Yahr stage 2-3 Parkinson’s disease whom had fallen. Future research should determine the optimum tool to assess frailty in this at risk population and delineate the association between Parkinson’s and frailty features and longer term outcomes.
- |||||||||| rivastigmine / generics
Rivastigmine for visual hallucinations in Parkinson’s disease (Agora 3 West, Level 3) - Sep 24, 2019 - Abstract #MDSCongress2019MDS_467;
Future research should determine the optimum tool to assess frailty in this at risk population and delineate the association between Parkinson’s and frailty features and longer term outcomes. Since rivastigmine treatment is lacking short-term benefits, the use in non-demented PD patients is not recommended.
- |||||||||| quetiapine / Generic Mfg.
Potential treatment considerations for refractory REM behavior disorder (Les Muses Terrace, Level 3) - Sep 24, 2019 - Abstract #MDSCongress2019MDS_366;
Additional trials with more patients may be needed to confirm the efficacy of these pharmacological treatment options. Treatment of RBD can help to prevent injuries to the patient and their bed partner.
- |||||||||| donepezil / generics, galantamine hydrobromide / generics, rivastigmine / generics
INTERVENTIONS TO ENHANCE SLEEP IN MILD COGNITIVE IMPAIRMENT AND MILD ALZHEIMER’S DEMENTIA: A SYSTEMATIC REVIEW (Board #340t - Exhibition) - Sep 17, 2019 - Abstract #WSS2019WSS_1938;
There is currently a lack of high quality studies targeting interventions for sleep disturbances in people at risk of, or with early evidence of AD. Our overall conclusion is that few well-designed studies have capitalised on the range of psychological, pharmacological, technological and lifestyle approaches that might benefit this patient population.
- |||||||||| rivastigmine / generics
Biomarker, Clinical, Journal: Ghrelin cascade changes in the peripheral blood of Japanese patients with Alzheimer's disease. (Pubmed Central) - Sep 14, 2019
The mRNA expression levels of MBOAT4 and GHS-R1b were significantly higher in AD subjects than in controls (MBOAT4: 1.10 ± 0.48 vs. 1.0 ± 0.55, p = 0.049; GHS-R1b: 1.76 ± 3.18 vs. 1.0 ± 1.56, p = 0.030). These changes in the ghrelin cascade in peripheral blood may reflect those in the brain, and may be a neuroprotective biomarker in AD.
- |||||||||| rivastigmine / generics
Treatment of anticholinergic delirium with rivastigmine. () - Sep 10, 2019 - Abstract #EUSEM2019EUSEM_1585;
The patient is known with a severe pychotic disorder, for which he is treated with a high dosis of antipsychotics (haloperidol, levomeprozamine, risperdone) and benzodiazepines (clonazepam and bromazepam). NO
- |||||||||| donepezil / generics, galantamine hydrobromide / generics, rivastigmine / generics
Retrospective data, Review, Journal, HEOR: Comparative Effectiveness and Safety of Cognitive Enhancers for Treating Alzheimer's Disease: Systematic Review and Network Metaanalysis. (Pubmed Central) - Sep 7, 2019
An exhaustive review of the literature involving 142 studies demonstrated that cognitive enhancers in general have minimal effects on cognition according to minimal clinically important difference and global ratings. The drugs appear safe, but this must be interpreted cautiously because trial participants may have less comorbidity and fewer adverse effects than those treated with these drugs in clinical practice.
|
